Institutional investors purchased a net $93.8 million shares of ZTS during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 95.01% of the shares outstanding that institutional investors hold is among the lowest in the Pharmaceuticals: Generic industry.
| Individual stakeholders | 87.00% |
| Other institutional | 77.67% |
| Mutual fund holders | 17.34% |